

CERTIFICATE

INFORMED CONSENT FORM

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlology-5)

This is to certify that the Translations done from English to Bengali is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Translation from English to Bengali

Date of Translation: 22-Apr-2026

DONE BY

Name of Translator: Ms. Champa Das

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 22-Apr-2026

By: Ms. Kankana C

Esther.D

Esther.D (Apr 22, 2026 16:06:30 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

Master Clinical ICF Version Date: 18 Feb 2026, Version Number: 1.0

Site Clinical ICF Version Date: 08 Apr 2026, Version Number: 1.1.0

PI: Dr. Jeevan Kumar; Site: Tata Medical Center



CERTIFICATE

INFORMED CONSENT FORM

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlology-5)

This is to certify that the Back Translations done from Bengali to English is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Back Translation from Bengali to English

Date of Back Translation: 22-Apr-2026

DONE BY

Name of Translator: Ms. Kushal Lahan

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 22-Apr-2026

By: Ms. Pinakshi Dutta

Esther.D

Esther.D (Apr 22, 2026 16:06:30 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

Master Clinical ICF Version Date: 18 Feb 2026, Version Number: 1.0

Site Clinical ICF Version Date: 08 Apr 2026, Version Number: 1.1.0

PI: Dr. Jeevan Kumar; Site: Tata Medical Center



CERTIFICATE

WITHDRAWAL INFORMED CONSENT FORM

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlology-5)

This is to certify that the Translations done from English to Bengali is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Translation from English to Bengali

Date of Translation: 22-Apr-2026

DONE BY

Name of Translator: Ms. Champa Das

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 22-Apr-2026

By: Ms. Kankana C

Esther.D

Esther.D (Apr 22, 2026 16:06:30 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

Master Withdrawal Informed Consent Form Version Date: 17 Feb 2026 Version No.:1.0

Site Withdrawal Informed Consent Form Version Date: 08 April 2026 Version No.:1.1.0

PI: Dr. Jeevan Kumar; PI: Tata Medical Center



CERTIFICATE

WITHDRAWAL INFORMED CONSENT FORM

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlogy-5)

This is to certify that the Back Translations done from Bengali to English is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Back Translation from Bengali to English

Date of Back Translation: 22-Apr-2026

DONE BY

Name of Translator: Ms. Kushal Lahan

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 22-Apr-2026

By: Ms. Pinakshi Dutta

Esther.D

Esther.D (Apr 22, 2026 16:06:30 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

Master Withdrawal Informed Consent Form Version Date: 17 Feb 2026 Version No.:1.0

Site Withdrawal Informed Consent Form Version Date: 08 April 2026 Version No.:1.1.0

PI: Dr. Jeevan Kumar; PI: Tata Medical Center



CERTIFICATE

PREGNANCY IN CLINICAL STUDY INFORMED CONSENT FORM

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlology-5)

This is to certify that the Translations done from English to Bengali is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Translation from English to Bengali

Date of Translation: 22-Apr-2026

DONE BY

Name of Translator: Ms. Champa Das

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 22-Apr-2026

By: Ms. Kankana C

Esther.D

Esther.D (Apr 22, 2026 16:06:30 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

Master Pregnancy in Clinical Study ICF Version Date: 17 Feb 2026, Version Number: 1.0

Site Pregnancy in Clinical Study ICF Version Date: 14 Apr 2026, Version Number: 2.1.0

PI: Dr. Jeevan Kumar; Site: Tata Medical Center, Kolkata



CERTIFICATE

PREGNANCY IN CLINICAL STUDY INFORMED CONSENT FORM

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlology-5)

This is to certify that the Back Translations done from Bengali to English is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Back Translation from Bengali to English

Date of Back Translation: 22-Apr-2026

DONE BY

Name of Translator: Ms. Kushal Lahan

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 22-Apr-2026

By: Ms. Pinakshi Dutta

Esther.D

Esther.D (Apr 22, 2026 16:06:30 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

Master Pregnancy in Clinical Study ICF Version Date: 17 Feb 2026, Version Number: 1.0

Site Pregnancy in Clinical Study ICF Version Date: 14 Apr 2026, Version Number: 2.1.0

PI: Dr. Jeevan Kumar; Site: Tata Medical Center, Kolkata

